论文部分内容阅读
作者等检测了67个化合物对晚期白血病L1210小鼠延长生存时间的能力,以甲氨喋呤的抗白血病的活力作为标准,观察平均生存时间。2,5-双(乙撑亚胺)-苯醌-3,6-二乙酰胺和4-双(β-氯乙基)氨基-偶氮-咪唑-5-甲酰胺的作用分别为甲氨喋呤的74%和176%;有显著活力的双氯乙亚硝脲(BCNU)和氯乙亚硝脲在本试验中仍有效;另外,试验了8个硝基脲衍生物,显示有显著的抗白血病活力。本文并报导了4-二甲氨基-偶氮咪唑-5-甲酰胺、阿糖胞苷、6-甲硫嘌呤核苷和6个硝基脲衍生物的治疗开始时间、治疗方案和给药途径与抗肿瘤作
The authors tested the ability of 67 compounds to prolong survival in late-stage leukemia L1210 mice and methotrexate’s anti-leukemic activity as a standard to observe the mean survival time. The effects of 2,5-bis (ethyleneimine) -benzoquinone-3,6-diacetamide and 4-bis (β-chloroethyl) amino-azo-imidazole- 74% and 176% of the neopterin; BCNU and BCA with significant viability were still valid in this study; in addition, eight nitro-urea derivatives were tested and showed significant Anti-leukemia activity. This article also reports on the initiation, treatment and route of administration of 4-dimethylamino-azimidazole-5-carboxamide, cytarabine, 6-methylthiopurine and 6 nitrourea derivatives And anti-tumor made